Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2020 07:48 ET | Source: Oxford BioMedica plc

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB)...